Subgroups
Bayer HealthCare
-
Tuesday - June 2, 2009
Bayer HealthCare and Genzyme Finalize Strategic Alliance Agreement
-
Monday - June 1, 2009
Bayer and Onyx Initiate Phase III Trial of Nexavar® in Non-small Cell Lung Cancer
-
Saturday - May 30, 2009
45th American Society of Clinical Oncology Annual Meeting (ASCO):
Bayer Schering Pharma Announces New Data on Novel Anti-cancer Compound BAY 73-4506
-
Thursday - May 28, 2009
Award sponsored by the Association of German Medical Journalists (VDMJ) and Bayer HealthCare AG
European Journalists’ Prize goes to Volker Stollorz
-
Thursday - May 28, 2009
Venous Blood Clot Prevention after Hip or Knee Replacement Surgery:
U.S. FDA Issues Complete Response Letter for Rivaroxaban
No new clinical or non-clinical studies to be conducted as a pre-requisite for approval
-
Thursday - May 28, 2009
Phase III Trial Started to Evaluate Combination Therapy of Nexavar® and Tarceva® in Patients with Liver Cancer
-
Friday - May 22, 2009
45th Annual Meeting of the American Society of Clinical Oncology (ASCO):
Bayer Schering Pharma To Present Data on Oncology Development Compound BAY 73-4506
-
Wednesday - May 20, 2009
Nexavar® Approved in Japan for the Treatment of Advanced Liver Cancer
-
Tuesday - May 19, 2009
American Thoracic Society (ATS) congress, San Diego, USA:
Bayer Schering Pharma presents positive results of phase II study with Riociguat
-
Friday - May 15, 2009
Targeted therapies: Improving outcomes for patients with cancer
-
Friday - May 15, 2009
Bayer and Onyx Announce Nexavar® Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
-
Thursday - May 14, 2009
Qlaira® – innovative estradiol-based oral contraceptive available in Europe from May onwards
A new oral contraceptive delivering the same estrogen as produced by the female body
-
Tuesday - May 12, 2009
Annual Stockholders’ Meeting
“Corporate strategy proves effective in a difficult environment”
Address by Werner Wenning, Chairman of the Board of Management
-
Monday - May 11, 2009
Award sponsored by the Association of German Medical Journalists (VDMJ) and Bayer HealthCare AG
Advances in Renal Cancer Journalists’ Award Europe goes to Malini Guha
-
Tuesday - May 5, 2009
Bayer Schering Pharma is starting Phase III studies with an innovative low-dose contraceptive patch
-
Thursday - April 30, 2009
Never stop dreaming
“With the right motivation, you can reach your goal”
Bayer Diabetes Care DreamFund™ winner cycles 2,000 miles across Europe
-
Thursday - April 30, 2009
Bayer and Regeneron extend development program for VEGF Trap-Eye
Two phase III studies in Central Retinal Vein Occlusion (CRVO) to begin in the second half of this year
-
Wednesday - April 29, 2009
Bayer interim report for the first quarter of 2009
CropScience and Pharmaceuticals continue on a path of growth – Slump in business at MaterialScience leaves a distinct mark
Group sales: EUR 7,895 million (minus 7.5 percent) / EBITDA before special items: EUR 1,695 million (minus 22.4 percent) / EBIT before special items: EUR 1,017 million (minus 32.1 percent) / Net cash flow: EUR 693 million (plus 31.3 percent)
-
Monday - April 27, 2009
Phase III Trial of Nexavar® in Chemotherapy-Naive Patients with Advanced Melanoma Does Not Meet Primary Endpoint
Study stopped based on interim analysis
-
Wednesday - April 22, 2009
3rd European Media Workshop on Diabetes:
Blood glucose monitoring – the underrated key to successful therapy
Bayer HealthCare Diabetes Care helps simplify life for patients with diabetes and their health care providers
Search
Publications
Stockholders' Newsletter
Annual Report
Sustainable Development Report
The Bayer Climate Program
research – The Bayer Scientific Magazine
Publications Overview
Newsletter
EventsFriday, February 26, 2010
Annual Report 2009 / Financial News Conference Full Year 2009
Contact: Günter Forneck
Additional Press Events
Investor Relations Events
Sport Events
BayKomm Events
Download Center - Selection